- In October 2021, BioNTech expanded its infectious disease portfolio capabilities by acquiring PhagoMed Biopharma GmbH, an Austrian biotechnology company, specialized in the development of a new class of antibacterials.
- PhagoMed BioPharma GmbH now is BioNTech R&D (Austria) GmbH.
The full press release on BioNTech's third quarter 2021 financial results and corporate update is available here: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-third-quarter-2021-financial-results-and
This LinkedIn post provides some insights on the deal: https://www.linkedin.com/posts/alexanderbelcredi_lorenzo-corsini-and-myself-are-super-happy-activity-6863874159173279744-i_uZ